Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of the stock in a transaction that occurred on Tuesday, June 11th. The stock was sold at an average price of $8.45, for a total value of $96,727.15. Following the completion of the sale, the director now directly owns 7,188,563 shares of the company’s stock, valued at $60,743,357.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.66, for a total transaction of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total transaction of $100,962.54.
• On Tuesday, March 19th, Blake Borgeson sold 20,054 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $10.79, for a total transaction of $216,382.66.

Recursion Pharmaceuticals Stock Down 1.9 %

NASDAQ:RXRX opened at $9.26 on Friday. The firm’s 50 day moving average is $8.69 and its 200 day moving average is $9.82. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the prior year, the firm earned ($0.34) EPS. The business’s revenue for the quarter was up 14.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on RXRX shares. KeyCorp increased their price target on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Monday, March 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Friday, May 10th.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. National Bank of Canada FI raised its position in shares of Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after purchasing an additional 1,500 shares during the period. Wedmont Private Capital grew its stake in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after buying an additional 2,000 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new stake in Recursion Pharmaceuticals during the 1st quarter valued at $26,000. Victory Capital Management Inc. lifted its position in shares of Recursion Pharmaceuticals by 23.6% during the third quarter. Victory Capital Management Inc. now owns 15,246 shares of the company’s stock worth $117,000 after acquiring an additional 2,912 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Recursion Pharmaceuticals by 8.5% in the fourth quarter. Arizona State Retirement System now owns 39,926 shares of the company’s stock worth $394,000 after acquiring an additional 3,125 shares during the period. Institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.